Adrian Noriega Aldave, MD
Pulmonary Disease · Montgomery, ALNPI 1558626010
Payments from drug & device makers
What this record shows
26 manufacturers reported payments, led by Intuitive Surgical at 50.0% of the total. 2025 is the largest year on record at $6,761, more than ten times the $487 reported in 2019.
Across 307 payments — averaging $37.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$6K
- GSK$2K
- AstraZeneca$660
- Boehringer Ingelheim$531
- Regeneron Healthcare Solutions, Inc.$394
- Insmed, Inc.$334
- plus $2K from 20 others
What the payments were for
- Food & beverage$5,84451%
- Education$5,53449%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 7 | $5,684 |
| GSK | 122 | $2,177 |
| AstraZeneca(2 entities) | 40 | $660 |
| Boehringer Ingelheim | 25 | $531 |
| Regeneron Healthcare Solutions, Inc. | 15 | $394 |
| Insmed, Inc. | 14 | $334 |
| Grifols USA, LLC | 14 | $299 |
| Mylan Specialty L.p. | 17 | $290 |
| Gilead | 9 | $172 |
| Genentech USA, Inc. | 8 | $133 |
| Sanofi | 6 | $126 |
| Philips North America LLC | 5 | $95 |
| Jazz Pharmaceuticals Inc. | 3 | $78 |
| Viatris Specialty LLC | 3 | $69 |
| Electromed, Inc. | 5 | $52 |
| United Therapeutics Corporation | 2 | $47 |
| Axsome Therapeutics, Inc. | 2 | $43 |
| Paratek Pharmaceuticals, Inc. | 2 | $36 |
| Olympus America Inc. | 1 | $28 |
| Fisher & Paykel Healthcare Inc | 1 | $26 |
| Merck | 1 | $23 |
| Circassia Inc. | 1 | $20 |
| Actelion Pharmaceuticals US, Inc. | 1 | $17 |
| Verona Pharma, Inc. | 1 | $16 |
| Inogen, Inc. | 1 | $15 |
| 3b Medical, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$5,500
- AREXVY$240
- TRELEGY ELLIPTA$119
How this compares
$11,378 in reported general payments places this provider in the 80th percentile of 215 pulmonary disease providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OfevNintedanib Esylate | 39 | $518,347 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 565 | $423,357 |
| ArikayceAmikacin Liposomal/Neb.Accessr | 14 | $212,112 |
| Spiriva RespimatTiotropium Bromide | 179 | $109,462 |
| Dupixent PenDupilumab | 23 | $84,988 |
| Breo ElliptaFluticasone/Vilanterol | 141 | $65,431 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 80 | $51,807 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 95 | $50,421 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 72 | $35,181 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 102 | $12,395 |
| SymbicortBudesonide/Formoterol Fumarate | 38 | $11,623 |
| Wixela InhubFluticasone Propion/Salmeterol | 57 | $9,356 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 297 | $6,551 |
| Arnuity ElliptaFluticasone Furoate | 21 | $5,812 |
| Incruse ElliptaUmeclidinium Bromide | 11 | $3,645 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimOfev, Spiriva Respimat, Stiolto Respimat | $531 | $678,230313 claims |
| GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Arnuity Ellipta, Incruse Ellipta | $2,177 | $533,426810 claims |
| Insmed, Inc.Arikayce | $334 | $212,11214 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $660 | $63,430118 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 215 pulmonary disease providers in Alabama.
Other pulmonary disease in Montgomery
- William SaliskiMontgomery$257K
- Apurva BansalMontgomery$15K
- Walter GribbenMontgomery$13K
- Priyanka VyasMontgomery$12K
- Lisa WilliamsMontgomery$9K
- Emily RehbergSylacauga$166K
- Tejaswini KulkarniBirmingham$134K
- Adrian DivittorioMobile$100K
- Luther CorleyHuntsville$86K
- Peter LutzMobile$63K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.